Adaptimmune

Adaptimmune Investor Day

April 18, 2024

Presentation Recording

Latest News

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Read Press Release View All Press Releases

Corporate Deck

Adaptimmune Corporate Deck March 2024

View Presentation View All Presentations

Investor Relations Contact Information

T: 215-825-9306

IR@adaptimmune.com

For other contact information, please visit the Contact page.